Skip to content
INTENDED FOR RESEARCH PURPOSES ONLY

Melanotan 2 and Hair Colour: What Can Be Claimed?

Split illustration of auburn and brown hair with question marks

Visitors sometimes ask whether Melanotan 2 will darken head hair, roots or grey hair. A claim about darker-looking skin does not establish a predictable change in hair colour. This article separates those questions and explains why confident colour and timing promises are not supported by the guidance cited here.

Skin pigmentation is a different question

Cancer Research UK describes Melanotan as a product that can stimulate pigment cells and make skin appear darker. Its guidance does not provide a reliable shade chart, success rate or timeframe for scalp hair. It would be misleading to turn a statement about skin appearance into “most people’s hair becomes several shades darker.”

The 1996 phase-I Melanotan II pilot study involved three male volunteers. Its abstract reports increased skin pigmentation in two participants, assessed by reflectance measurements and visual observation. It does not report a scalp-hair colour assessment. Those findings therefore cannot establish whether MT2 darkens head hair, changes roots or produces a particular hair shade.

Can photographs establish a hair-colour change?

A before-and-after photo also cannot establish what caused a change in hair appearance, including lighting, dye or a naturally changing colour. A product claim about hair needs evidence for the exact outcome, not an analogy to skin.

A useful comparison would keep the lighting, camera settings, hair preparation and viewing angle consistent. It would also record dye, other products and the interval between images. Even a carefully matched pair of photographs would need a suitable comparison group and a defined measurement method before attributing the difference to MT2.

Is there evidence for grey-hair repigmentation?

The sources reviewed here do not establish that Melanotan 2 reverses grey hair, that grey hair cannot respond, or that visible changes should begin within one or two weeks. Each of those statements would need evidence that measures the specific hair outcome.

Research on another pigment-related peptide illustrates why the compound matters. A prospective case series involving 14 people assessed a topical palmitoyl tetrapeptide-20 lotion over six months. The authors concluded that their findings did not support its efficacy for hair repigmentation. That substance and formulation are different from Melanotan II. The study cannot establish an MT2 benefit or prove that every pigment-related compound has the same effects.

Hair-colour questions: evidence and limits

What the reviewed evidence can and cannot establish
Question Evidence reviewed Claim not justified
Does MT2 darken head hair? The early MT-II trial reports skin measurements, not a scalp-hair assessment. A predictable hair shade, success rate or timing.
Does it reverse grey hair? The cited hair case series studied a different peptide and formulation. Transferring another compound’s results to MT2.
Can a photo prove a response? An image may show an apparent difference without establishing its cause. Treating an uncontrolled before-and-after image as proof.

What would a convincing hair-colour study need?

The outcome needs to be defined before interpreting the result. A study should distinguish scalp hair from skin, natural colour from dyed hair, and newly grown hair from changes in photographic appearance. It should identify the tested substance and preparation, explain how colour was measured, and report the comparison and follow-up. A biological explanation alone does not supply those observations.

What remains unknown?

The reviewed sources do not provide an MT2 hair-colour success rate, a reliable timetable or evidence that a reported change would persist. Missing evidence leaves those questions open; it does not establish either a guaranteed effect or a guaranteed absence of one. Our Melanotan 2 science and risks overview explains the wider distinction between research findings and claims about products sold online.

Safety claims need their own evidence

Cancer Research UK advises against Melanotan nasal sprays and injections and says they have not been tested for safety, quality or effectiveness. The MHRA’s Melanotan II response also explains the safeguards missing from unauthorised products. Neither a hoped-for hair effect nor an online testimonial changes that assessment.

For a wider explanation of how to evaluate product assertions, read the source-evaluation guide. If you notice a new or changing mole or another concerning skin change, seek advice from a qualified healthcare professional.

Sources checked: 2 November 2026. General information, not a diagnosis or treatment recommendation.

Read hair-colour results without converting uncertainty into a promise

The discussion above explains why skin findings and studies of other substances cannot establish an MT2 hair-colour promise. A further distinction concerns how a result is reported. Words such as improved, darker and unchanged need an explicit meaning before a reader can compare them or apply a study summary to a particular hair-colour question.

Check what the reported colour category includes

A category such as darker can combine several different observations unless the report defines it. A small measured difference, a noticeable visual difference and a participant’s preferred appearance are not identical outcomes. If they are grouped under one word, the summary needs to explain the grouping. A descriptive label alone does not provide a particular shade change or a reliable personal expectation.

Distinguish a group average from the number who changed

An average result does not show how many individuals had a similar result. A report needs the number assessed and an appropriate account of the variation before a reader can understand the group summary. Equally, selected examples do not supply the missing denominator. A few striking images should not be turned into most people, and a group average should not be presented as everyone’s outcome.

Leave missing observations out of the success count

If a later assessment is unavailable, that absence is not an observed improvement or an observed failure. The report should distinguish those with recorded follow-up from those without it. Otherwise, the denominator can change invisibly between the starting group and the final claim. This is a question about interpreting a record; it does not establish any particular MT2 hair response or timeframe.

Keep the conclusion tied to the named substance and outcome

A negative result for another preparation cannot settle every question about MT2, just as a favourable observation for another substance cannot establish an MT2 benefit. The evidence overview explains this connection between the claim and the tested subject. For this hair question, the appropriate conclusion remains limited: the sources discussed here do not establish a predictable MT2 shade change, grey-hair response or timetable. A broader claim would need evidence that actually addresses it.

References checked: 14 November 2026.